(Q37166379)

18 August 2017

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors (English)

1 reference

18 August 2017

8

Suzanne Kamel-Reid

0 references

Philippe L. Bedard

object named as

Philippe L Bedard

17

0 references

Blaise A Clarke

object named as

Blaise A Clarke

4

0 references

author name string

Ivan Diaz-Padilla

1

1 reference

18 August 2017

Hal Hirte

2

1 reference

18 August 2017

Amit M Oza

3

1 reference

18 August 2017

Brenda Cohen

5

1 reference

18 August 2017

Michael Reedjik

6

1 reference

18 August 2017

Tong Zhang

7

1 reference

18 August 2017

S Percy Ivy

9

1 reference

18 August 2017

Sebastien J Hotte

10

1 reference

18 August 2017

Albiruni A R Razak

11

1 reference

18 August 2017

Eric X Chen

12

1 reference

18 August 2017

Irene Brana

13

1 reference

18 August 2017

Monika Wizemann

14

1 reference

18 August 2017

Lisa Wang

15

1 reference

18 August 2017

Lillian L Siu

16

1 reference

18 August 2017

17 July 2013

1 reference

Investigational New Drugs

18 August 2017

1 reference

18 August 2017

31

1 reference

18 August 2017

5

1 reference

18 August 2017

1182-1191

1 reference

Creative Commons Attribution-NonCommercial 2.0 Generic

18 August 2017

start time

1 October 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10637-013-0001-5

0 references

cites work

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Therapeutic antibody targeting of individual Notch receptors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Rational targeting of Notch signaling in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

High-level JAG1 mRNA and protein predict poor outcome in breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Notch signaling: cell fate control and signal integration in development

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3771370

10.1007/S10637-013-0001-5

3 September 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

1 reference